Revenio Group (REG1V) Q3 2026 earnings summary

Executive summary

• Q3 net sales rose 127.5% YoY to €58.8m, largely reflecting the Visionix acquisition; organic sales were flat and comparable pro forma sales declined 0.5%.

• Integration advanced to plan, with 25% of the ~€20m synergy target completed; focus is shifting toward commercial synergies.

Financial highlights

• Q3 adjusted EBITA was €8.7m, up 30.3%, with a 14.7% margin; adjusted EBITDA was €10.2m, up 38.9%.

• Q3 reported EBIT was €3.6m versus €6.0m; profit was €3.4m versus €4.6m, and EPS was €0.116 versus €0.173.

• 9M sales were €125.4m, up 59.8%; adjusted EBITA was €21.7m, up 4.7%, and adjusted EBITDA was €24.9m, up 9.1%.

• Q3 operating cash flow was €5.5m versus €3.0m, supported by working capital and reduced by €2.0m of integration payments; 9M operating cash flow was negative €0.3m.

Outlook and guidance

• 2026 currency-adjusted net sales guidance narrowed to €190m–€200m from €190m–€205m; adjusted EBITA margin is expected to remain satisfactory.

• The lower end assumes continued soft demand and slower customer activity; the upper end depends on market improvement and successful commercial initiatives.

• APAC weakness, North American sales reorganization effects and component cost pressures weigh on the outlook; ILLUME FDA approval timing shifted toward Q3–Q4 2027.